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Chemotherapy for Brain Metastasis
Sees Progress in the Last Decade
Cancer researchers have traditionally had little confidence in
chemotherapy for brain tumors.
Because of the "blood-brain
barrier," the consensus was that
systemically administered agents
would never reach the tumor or,
if they did, only in such small
quantities that the tumor would
not
respond.
Jin S. Lee
Several reports over the past
decade, however, suggest that the blood-brain barrier may
not be so formidable.
"The existence of a blood-brain barrier does not necessarily mean that a blood-tumor barrier exists," said Jin S. Lee,
M.D., Department of Medical Oncology, The University of
Texas M. D. Anderson Cancer Center. "Even a brain tumor
needs blood to survive, and if it is receiving a supply of blood
from the general circulation, it stands to reason that systemic
chemotherapy would reach the tumor."
Last year, Lee and his colleagues established just such a
possibility in a report that showed that brain metastases in
patients with small cell lung cancer do respond to chemotherapy. The study ·was important because it was "the first
prospective study to demonstrate that chemotherapy given
as initial treatment for metastatic small cell lung cancer could
produce an objective tumor response in the brain," Lee said.
The key words are "initial treatment." Studies of other
types of primary tumors have concluded that systemic
chemotherapy reduces brain tumors. But though the results
were highly suggestive, they were not conclusive because
the patients had received or were receiving other therapy,
such as radiation, corticosteroids, or intrathecal injections.

Some Studies Promising but Not Conclusive
In 1983, Dutzu Rosner, M.D., and his colleagues from
the Roswell Park Memorial Institute gave 66 breast cancer
patients with brain metastasis (42 of whom had been pre-

viously treated) various combinations of cyclophosphamide,
5-fluorouracil, methotrexate, vincristine, and prednisone.
Thirty-four patients achieved objective tumor responses, but
the addition of prednisone led some members of the research
community to question the study. Since prednisone reduces
swelling, it may have skewed the brain scan results.
Three years later, another promising study was published.
Gordon Rustin, M.D., and his team at Charing Cross
Hospital ih London, England, treated 147 patients who had
nonseminomatous germ cell tumors. Of the 10 patients who
had brain metastases, eight were alive at the time of the report
(1985). But because the regimen included intrathecal methcontinued on page 2
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corroborated by future studies, may forc e investigators
to reevaluate tpe conventional methods of treating brain
metastasis. Currently, most protocols rely on radiation.

otrexate, the efficacy of the drugs administered intravenously could not be established.
Though not conclusive, these investigations deserved
attention. By the time of Rustin and coworkers' report,
Lee and his team had already set out to evaluate the efficacy
of systemic intravenous chemotherapy in metastatic small
cell lung cancer. This cancer was chosen because of its chem osensitivity and because 10% of the patients have brain
metastasis at initial diagnosis. Lee's study was the first
"clean" study, since it examined patients who had not yet
been treated and who were given no other concurrent
treatment during the first three courses of intravenous chem otherapy.

Current Strategies Must Be Reevaluated
"Knowing that chemotherapy is effective, we can hold
off on radiation treatment initially. We would want to order
a CT scan immediately to determine if a metastatic brain
lesion is present, but even if it is, we have the option of
waiting to see if the chemotherapy will take care of the
primary tumor and the brain metastasis," Lee said.
This treatment strategy may be better than current strategies for two other reasons, Lee said. First, radiation, when
given concurrently with chemotherapy, increases the already
significant myelosuppression caused by chemotherapy. And
second, most patients also have disease in areas other than
the brain, and though radiation can effectively induce local
tumor responses of up to six months, it does not affect
systemic disease. "Ultimately, cure will most likely require
a systemic component," Lee said.

Nine of Eleven Patients Achieve Objective
Tumor Response
Fourteen patients were initially entered on the study.
Eight patients had a single metastatic brain lesion, and six
had multiple lesions, as documented by computed tomographic ( CT) scans. Two died early because of sepsis, and
one had radiation after the first course of chemotherapy
when the primary lung lesion progressed. Eleven patients
therefore were evaluable for response after initial chemotherapy with no other concurrent treatment.
The chemotherapy consisted of 600 mg/m 2 of cyclophosphamide and 50 mg/ m2 of doxorubicin on day 1, 60

Radiation Exacerbates Myelosuppression
Radiotherapy's exacerbation of chemotherapy-induced
myelosuppression has not always been acknowledged.
Irradiation of less than 25% of the bone marrow generally
was considered to be well tolerated, and because the skull
contains less than 10% of the bone marrow, researchers
believed that whole-brain irradiation had no significant
myelosuppressive sequelae. This may have been true for
radiation given alone, but Lee and his colleagues noticed
that radiation seemed to increase the myelosuppressive
effects of combination chemotherapy. In the early 1980s,
Lee and his team set out to examine this issue, and their
results, like those of their more recent study, challenged
conventional thinking.
Their study of 48 patients with metastatic small cell
lung cancer was published in 1986 and compared 24
patients who received three courses of combination chemotherapy (etoposide, cyclophosphamide, doxorubicin, and
vincristine) with 24 patients who received the chemotherapy and concurrent irradiation ( 3000 rad in 10 fractions
over two weeks).
They found that the irradiated patients indeed had more
severe suppression of white blood cell counts and platelet
counts and, not surprisingly, a higher incidence of infection.
In addition, the increased severity of myelosuppression occurred in spite of the fact that 11 of the irradiated patients
had to have chemotherapy dose reductions, as opposed to
three in the control group.
Nevertheless, Lee by no means advocates eliminating
radiation as therapy for brain metastasis. In the more recent

mg/m 2 of etoposide on days 3 through 5, and 1.5 mg of
vincristine on days 1 and 5, all of which were administered
intravenously. Of the 11 evaluable patients, eight achieved
a partial remission, defined as a 50% reduction in all measurable lesions for at least four weeks, and one achieved a
complete remission, defined as the absence of all signs and
symptoms of tumor for four weeks. The median survival
was 34 weeks (range, 1 to 93), whereas for untreated
patients it is generally less than eight weeks.
"This study was important not only because it showed
that systemic chemotherapy alone can induce the objective
regression of metastatic brain lesions, but also because
the regression occurred rather promptly after chemotherapy," Lee said. Such promptness in tumor regression, if

continued on page 7
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lmmunocytochemical Assays for Steroid Receptors:
A New Application for Fine Needle Aspiration
At The University of Texas

labeled estradiol that binds to the active site of the receptor. Estrogen receptor status can then be quantified by
tracking the radioactive estradiol. Though the assay is
useful, it can be affected by endogenous estrogen production. If endogenous estrogen occupies the receptors, the
labeled estradiol has no place to bind; thus estrogen
receptor content may be underestimated. "Such is often
the case in younger women," Katz said, "since they
produce a lot of estrogen."

M. D. Anderson Cancer
Center, breast cancer is rou tinely diagnosed by examining
tumor tissue aspirated by
needle. If the tumor is malignant, then other assays, such as
those for estrogen receptors,
are performed. But until
recently, determination of
Ruth L. Kotz
estrogen receptor status could
only be performed on surgically obtained tissue. Though
medically routine, an excisional biopsy is an additional
stress for patients trying to cope with the diagnosis. Fortunately, new immunocytochemical assays for estrogen
receptors make surgi~al biopsy unnecessary. Because the
new assays require much less tissue than that needed for
standard biochemical assays, they can be performed on
tissue obtained by fine needle aspiration. Better still, the
new assays may prove more accurate than the biochemical
assays, said Ruth L. Katz, M.D., chief of the Section of
Cytology at The University of Texas M. D. Anderson
Cancer Center.
The medical community has long known that assays of
estrogen receptor status provide useful prognostic and
therapeutic information, said Katz. For more than 20 years,
biochemical assays using radioimmunoassay methods have
been the standard for determining estrogen receptor status.
But the assays require 0.5 to 1 gram of tissue, which can
only be obtained surgically. Moreover, though the assays
help predict the potential for recurrence of stage I breast
cancer, they are only 5 5 to 60% accurate in predicting a
patient's response to hormonal therapy.

Instead of determining the patient's estrogen-binding
capacity, the immunocytochemical assay uses a monoclonal antibody, H222 Spy, that identifies a different, nonactive part of the receptor located away from the site that
actively binds the estrogen. Even if the active site is
occupied, the monoclonal antibody is able to bind to the
nonactive site. Because the immunocytochemical assay is
relatively new, most studies have been designed to compare it with the biochemical assay. In making these
comparisons, investigators focus on two measures: sensitivity ( the probability that an estrogen receptor-positive
tumor will be detected by the test) and specificity (the
probability that an estrogen receptor-negative tumor will
be negative by the test). A good test is both highly
sensitive and specific.
"It is crucial that false negatives be minimized," Katz
said, "since a test that incorrectly identifies the tumor as
negative for estrogen receptors may preclude the patient
from getting beneficial nontoxic hormonal or antiestrogen
therapy. The extremely high specificity of ERICA ensures
that hormonal or antiestrogen treatment can be correctly
planned for an overwhelming majority of patients."
Though specificity and sensitivity of the immunocytochemical assay vary among institutions, they consistently

New Assay Requires Less Tissue
The estrogen receptor imm11nacytatbemical assay
(ERICA), however, can be performed on as few as 100
cells, which can easily be obtained by fine needle aspiration. In addition, one study suggests that the new assay
may be a better predictor of disease-free survival than the
biochemical assay, Katz said. "Whether ERICA is better
than the biochemical assays in predicting response to
hormonal therapy still has to be substantiated, but I think
it will surpass the 55 to 60% accuracy of the biochemical
assays."
Both types of assays identify the estrogen receptor, but
each assay identifies a different aspect of the molecule. The
biochemical assays determine the amount of radioactively

continued on page 4
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immediately after procurement, whereas tissue procured
from surgical specimens such as mastectomies may be
devascularized for up to 45 minutes during surgery before
being sent to the pathologist. "Since estrogen receptors are
very labile, the timeliness of processing is very important,"
Katz said. "Even if the pathologist processes a mastectomy
specimen immediately, the estrogen receptors may still
have undergone some degradation during the period of
devascularization."
Receptor degradation can also be prevented by immediately freezing the surgical biopsy. "Before fine needle
aspiration, frozen section diagnosis would be made during
surgery. If the tumor was malignant, frozen-block tissue

compare favorably with the biochemical assays. At M. D.
Anderson, the sensitivity on cytological specimens is 94%.

Aspiration Is Ideal for New Assay
Needle aspiration is ideal for obtaining tissue for the
immunocytochemical assay. The procedure is routinely
performed at the M. D. Anderson Fine Needle Aspiration
Clinic, which is directed by Nour Sneige, M.D., associate
director of cytology.
Aspiration may be preferable to surgical biopsy for a num ber of other reasons. First, the procedure is less expensive
and easier to perform. Most patients undergo the procedure
as outpatients. Second, aspiration can sample very small
tumors for the estrogen receptor assay, and at the same
time tissue can be procured for microscopy. Third, aspiration may be the only practical method available when tumor
size or accessibility preclude surgical biopsy or if patients
present with metastases that need to be investigated for the

"
presence of the receptor. And finally, if the patient is to
receive preoperative chemotherapy or irradiation, aspirates
are an ideal means to determine estrogen receptor status
before these therapies alter the biochemistry of the tumor
or eradicate it altogether.
Fine needle aspirates also allow multiple samplings of
tumor, which, according to Katz, is an important advantage
because breast cancer is morphologically and biochemically
heterogeneous. By sampling multiple areas, the pathologist
can get a more accurate sense of the distribution of estrogenbinding cells in the tumor. Such is not the case with the
biochemical assays, which require the tissue sample to be
homogenized before processing; consequently, any attempt
at identifying the source and distribution of cells is very
difficult.

Aspirates Less Likely To Allow Receptor
Degradation

Figure 1. Breast cancer tissue stained with amonoclonal antibody that identifiesestrogen receptors. Cells
ore positive for the receptors, as indicated by the dork nuclear staining. Top, fine needle aspirate. Bottom,
histological section.

An additional advantage is that aspirates can be processed
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would be submitted to the pathologist for estrogen receptor assays; hence, in that situation the tissue would be fresh
and receptor degradation would be minimized," Katz said.
At M. D. Anderson, however, frozen section diagnosis is
less frequently used. "In years past, patients would have a
general idea of the diagnosis based on clinical and radiographic findings, but a definitive diagnosis would have to
be made during surgery. The patient would undergo the
operation with the understanding that, if the tumor were
malignant, then a mastectomy would be performed. With
fine needle aspiration, the patient doesn't have to be subjected to surgery without a definitive diagnosis."
She emphasized that because of the small study sample,
the results can only be considered preliminary, but if the
data are confirmed, then immunocytochemical analysis of
aspirates may emerge as the diagnostic procedure of choice.

Assay Also Used for Histology
Researchers at the M . D. Anderson Cancer Center are
focusing their efforts on refining the estrogen-receptor
immunocytochemical assay. (M. D. Anderson is currently

Continued Research on Prognostic
Factors Needed
Katz is encouraged by the developments in fine needle
aspiration and the immunocytochemical assay, but she
stressed that prognostic assay research has a long way to
go. "In addition to estrogen receptors, a lot of work is
being done nationwide on other prognostic factors, like
the neu oncogene, the multidrug resistance gene, progesterone receptors, flow cytometrically derived ploidy, and

implementing a similar test for progesterone receptors.)
The assay can be applied to histological sections of tumor,
as well as to the whole-cell aspirates examined cytologically.
Katz and her colleagues, in a study of 55 patients published
in the March-Ap ril issue of Breast Cancer Research and
Treatment (15:103 -115, 1990), for the most part confirmed
the immunocytochemical estrogen-receptor results of other
investigators. However, in contrast to other studies, Katz
and her team found that sensitivity and specificity of the
assay performed on cytological material (94% and 100%, respectively) were higher than those obtained using cryostat
(histological) sections (67% and 90%, respectively). In most
previous studies, the sensitivity and specificity of the histological sections were equal to or higher than the cytological
aspirates.
"The surprising thing initially was that the cytology was
more sensitive; however, after reviewing the literature, we
found several reports in which even the biochemical assays,
if performed promptly on biopsies, resulted in higher estrogen receptor values than if the same tissue was procured
following mastectomy," said Katz.

proliferative indices, but long-term studies will have to be
performed before we can tell whether they mean anything,
since a significant percentage of breast cancer patients may
live from 10 to 15 years after diagnosis and still have
recurrence. Nevertheless, as far as fine needle aspiration's
involvement in performing these assays is concerned, the
writing is on the wall. It's here to stay." ■

Physicians who desire additional information may write Ruth L. Katz,
M.D., Department of Pathology, Box 85, The University of Texas M. D .
Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas
77030, or call (713) 792-3140.
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Leukoplakia continued from page 8
toxicities seen with the higher dose induction therapy were
significantly lower during maintenance therapy, and the
side effects of low-dose therapy were mild, reversible, and
similar to those associated with beta-carotene. Some
research has been done with other vitamin A analogues,
including tretinoin and etretinate, but the availability of
these often is limited.
Most leukoplakia patients are men, by a 3-to-l margin.
That made it something of a surprise, Hong indicated, that

between placebo and therapy effects.
The clinical reversal ofleukoplakia by 13-cis-retinoic acid
was the most important finding, but in a more general context the histologic findings ultimately are more important,
Hong said, for they can "show the degree of dysplasiasevere, moderate, mild-or hyperplasia, with dysplasia being
more serious than hyperplasia. This information is important
when predicting whether a lesion will progress to squamous
cell carcinoma."
Though encouraged by the treatment's effectiveness,
Hong and his colleagues still had to address one obstacle:
duration of remission. After therapy stopped, lesions
recurred in nine patients.

Maintenance Therapy Prevents Relapse
The relapses indicated that the vitamin A analogue would
have to be given in a long-term chemoprevention regimen.
To that end, Hong and his team, in an ongoing study,
have treated 55 patients. As in the above-mentioned study,
patients received 1 to 2 mg/kg/day of 13-cis-retinoic acid
for three months. "This was quite effective in the first
study," Hong said, "except that the remissions achieved
did not last after therapy was halted. So we considered how
we could maintain these remissions."
The researchers added nine months of maintenance
therapy consisting of low-dose retinoic acid ( 0. 5 mg/kg/
day). They also administered 15 to 30 mg/day of betacarotene to another group of patients, since "some reports
indicated that beta-carotene was as effective as retinoic acid
against leukoplakia. And the beauty of beta-carotene is that
it has no side effects, except for inducing some yellowing of
the skin," said Hong.

women account for 35 of the first 55 patients in the current
M. D. Anderson trial. Hong was not sure why more women
than men were enrolled in this particular trial. The 12-month
study, which Hong called an intermediate-term investigation,
should be completed by year's end. He noted the need for
additional longer-term evaluation of low-dose vitamin A
analogue administration, as vitamin A toxicity is cumulative.

Lessons in Reversing Carcinogenesis

In addition to treating leukoplakia itself, "our goal is to
reverse carcinogenesis and to discover how retinoic acid
From results with the first 20 patients who completed
effects that reversal. Retinoic acid can reverse the carcinothe three-month induction and nine-month maintenance
genie process, but how? We are looking at some specific
therapy, "we found that low-dose retinoic acid appears to
biomarkers-Kl keratin, transglutaminase, involucrin (a dif~mor~dfeerivetha~beta-eamtrnN11terms-efn1aint.tin~-- - - -fc.....erentia1:iurrm~arker1~arrcrmicronudei~genotoxicnrarker~
ing remission," Hong said. So far, no relapses have been
as well as proliferating cell nuclear antigen."
seen among the nine patients who have completed mainteMicronuclei, which can be measured in tissue scrapings,
nance therapy with the low-dose retinoic acid, whereas 6 of
are formed from chromosome fragments in proliferating
11 who completed maintenance therapy with beta-carotene
cells and are created by such events as carcinogenic damhave had leukoplakia relapses. Side effects from low doses
age. Elevated counts appear to correlate with cancer risk in
of the vitamin A analogue are fairly minimal and at least
oral and other cancers. The low-dose retinoic acid maintetolerable, he said.
nance therapy in Hong and colleagues' ongoing study
The advantage of using an analogue of vitamin A is
further reduced micronuclei counts already lowered by the
that the analogue is less toxic to the liver than is vitamin
induction therapy in three of nine patients, whereas betaA itself. The major toxicity associated with retinoic acid is
carotene did not, according to a preliminary analysis by
to the skin, Hong said. The mucocutaneous and lipid
Scott Lippman, M.D., and colleagues at M. D. Anderson.

Retinoic Acid versus Beta-carotene
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Progress continued from page 2
study, even though chemotherapy was the primary focus,
all patients received radiation after the third course of
chemotherapy. In fact, objective tumor regression was
observed after whole-brain irradiation in all three patients
whose disease progressed during the initial chemotherapy
period.
"Since we know that certain cancers have a high probability of metastasizing to the brain, whole-brain irradiation can
be used prophylactically. By and large, radiation still has a
very important place in treatment," Lee said.

The measurement of drug effects may be confounded by
dietary factors. In fact, in some countries, dietary deficiencies are a major cause of leukoplakia. Hong noted that
whether some patients have better outcomes because they
eat more broccoli, for example, or take vitamin supplements is not known, although he cautions against routine
use of vitamin A supplements because of the vitamin's
cumulative toxicity.
Leukoplakia usually is caught early, often during routine
dental exams, Hong said. Research aimed at heading it off
or reversing it with retinoic acid, other vitamin A analogues, or other micronutrients such as beta -carotene likely
will also shed light on how squamous cell carcinomas
develop, and may eventually provide clues to preventing or
reversing this cancer. ■
Physicians who desire additional information may write Waun Ki Hong,
M .D., Box 80, Department of Medical Oncology, The University of
Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard,
Houston, Texas 77030, or call (713) 792-6363 .

0NCOLOG
President, The University ofTexas M. D. Anderson Cancer Center

Charles A. leMaistre, M.D.

More Effective Chemotherapy Is Needed

Vice President for Academic Affairs

The challenge at this point is to identify an even more
effective yet less toxic chemotherapeutic regimen. If such a
treatment can be identified, it may be possible to delay or
even omit radiation therapy to the brain, thereby reducing
the risk of severe myelosuppression and infection morbidities.
To this end, Lee and his team are evaluating a combination
of vincristine, etoposide, cisplatin, and cyclophosphamide.
(They have dropped doxorubicin because of its cardiotoxicity.)
"We still need to analyze the data," Lee said. "My feeling
is that this protocol is as effective as previous ones, but we're
still a long way from establishing a truly effective systemic
treatment." If such a regimen is identified, then researchers
can safely place the blood-brain barrier behind them and
begin to focus on new challenges in the treatment of cancer
patients. ■
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Researchers Hope Chemoprevention
Will Reverse Tumorigenic Process
may occur in tobacco users after they kick th habit.
Investigators have been looking for an alt rnati e to
surgery, the traditional treatment for se ral r a on :
The lesions often recur, and surg ry is impractical h n
the condition spreads across the inner surfac of th lip or
through other areas of the mouth in multipl 1 ion . In
1986, Hong and his colleagues reported a trial in hich
they examined an alternati e treatment: chemopre ention
with the vitamin A analogue 13-cis-retinoic acid ( ew
England Journal of Medicine 315:1501-1505 ).
Twenty-four patients who recei ed the itamin A analogue (1 to 2 mg/kg/day) were compared with 20
patients who received a placebo. Sixteen of the treated
patients ( 67%) achieved a complete (2 patients) or partial
( 14 patients) objective clinical response, compared with
two patients in the placebo group (10%), ho each achie ed
a partial response. Histologic anal sis of pre- and posttreatment biopsy specimens revealed d splasia re ersal in 13
treated patients and in 2 patients who recei ed the placebo.
The trial was halted early because of the striking differences

Unlocking the secret of how
retinoic acid prevents leukoplakia, a squamous cell carcinoma
precursor, may well reveal a
means of reversing carcinogenesis, said Waun Ki Hong,
M.D., who helped establish that
the vitamin A analogue actually
works to prevent or reverse
leukoplakia.
Waun Ki Hang
Hong is chief of the Section
of Head, Neck, and Thoracic Medical Oncology at The
University of Texas M . D. Anderson Cancer Center. He
and his colleagues are trying to refine a novel chemoprevention strategy for the precancerous lesions. Leukoplakia
progresses to oral squamous cell carcinoma in 5 to 15% of
patients from 1 to 20 years after it appears, and it spontaneously regresses in only 10%. The lesion affects 6 to 8% of
Americans, is usually asymptomatic, and most often is
caused by tobacco smoking or chewing or, less often, by
alcohol abuse. Spontaneous regression or risk reduction

continued an page 6
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